Anticoagulation Management in Atrial Fibrillation Patients with Chronic Anemia

Patient Assessment and Anticoagulation Decision

The American College of Cardiology recommends continuing apixaban in patients with atrial fibrillation and chronic anemia, with a hemoglobin level ≥10 g/dL, as the stroke prevention benefit outweighs bleeding risk, and the dose should be 5 mg twice daily unless ≥2 dose-reduction criteria are met: age ≥80 years, weight ≤60 kg, serum creatinine ≥1.5 mg/dL 1, 2
For patients with hemoglobin <10 g/dL, reassess stroke risk using CHA₂DS₂-VASc score—if score ≥4, anticoagulation benefit likely still outweighs risk, and apixaban remains preferred over warfarin due to lower bleeding rates 3
The American Heart Association recommends evaluating bleeding history and determining anemia etiology in patients with severe anemia, and considering temporary discontinuation of apixaban only if active bleeding is present, hemoglobin is acutely dropping, or anemia etiology suggests high ongoing bleeding risk 6

The American College of Chest Physicians recommends hemoglobin monitoring every 3-6 months, or more frequently if hemoglobin <10 g/dL, and renal function assessment every 3-6 months as anemia and renal impairment often coexist 8
Stool guaiac testing is recommended if gastrointestinal bleeding is suspected, and patient education on bleeding warning signs is essential 3

Temporary discontinuation of apixaban should be considered only in specific high-risk scenarios, such as active major bleeding, hemoglobin <8 g/dL with ongoing decline, recent intracerebral hemorrhage, or planned invasive procedure with high bleeding risk, and reassess stroke risk and plan for resumption once bleeding risk is mitigated 1, 5, 7